fbpx
Connect with us

News

AI study aims for earlier bowel cancer diagnosis

Researchers are using an AI technology to improve polyp detection.

Avatar photo

Published

on

Healthcare AI artificial Intelligence

Researchers from nine locations in England are using an AI technology to improve polyp detection during colonoscopies; allowing doctors to detect signs of bowel cancer at its earliest stages.

When diagnosed at its earliest stage more than 9 in 10 people with bowel cancer will survive their disease for over 5 years compared with 1 in 10 when it’s diagnosed late.

The study is hoping to recruit over 2000 participants before September 2022.

Colorectal cancer affects 1 in 15 men and 1 in 18 women in the UK with 16,600 deaths every year; it is the UK’s second most deadly cancer.

Bowel cancer starts when a polyp (or ‘adenoma’) progresses to cancer, but it can be prevented if detected early enough.

Colonoscopy is the ‘gold standard’ assessment for bowel cancer and Adenoma Detection Rate (ADR) (which measures how many polyps the doctor removes) has a notable impact on bowel cancer outcomes.

Studies have shown that just a one per cent increase in ADR is associated with a three per cent decrease in the risk for bowel cancer.

Previous studies which were limited by being undertaken in very specialist units, have shown that Medtronic’s GI Genius Module could lead to an absolute increase in ADR of 14 per cent.

The COLO-DETECT study hopes to support these findings with robust clinical data.

The study lead, professor of gastroenterology at Newcastle University, Prof. Colin Rees, said: “The introduction of AI into colonoscopies is a very exciting breakthrough and we have already seen that it has the potential to significantly increase ADR.

“Our aim is to assess how much GI Genius can improve ADR when compared to standard colonoscopies without AI. From this study we hope to gather evidence to further the adoption of AI into routine colonoscopy practice across the NHS, helping to reduce bowel cancer deaths across the UK.”

Dr Laura Neilson, consultant gastroenterologist, who was the first to recruit a patient into the trial, said: “Bowel cancer is entirely treatable and in most cases curable, especially if it’s diagnosed early – which is why this study is so important. COLO-DETECT is without question, world leading research and we are delighted to be the first hospital in the UK to recruit a patient into this trial and to be leading this pioneering research.”

Michael Anthony Watson, 58, from Sunderland, was invited to take part in the study last November as part of investigations after he started experiencing stomach pains.

The COLO-DETECT technology was used during his colonoscopy when it was carried out at South Tyneside District Hospital, where the Trust has set up its trial base, with the AI kit activated as part of the randomised study.

Michael said: “The clinician asked me if I wanted to take part in this study and I thought if it is going to benefit me, of course, but I knew it would also benefit others, so anything which could help, I was all for. When I went in, they told me the machine was switched on and I wouldn’t have known any different.

“I asked at the end how long it would be before they knew the results and I was told straight away there were no signs of bowel cancer, which was a relief. I know they’d also taken some biopsies, so they were still to check, but at least I knew then what they’d seen. If anyone else was asked to join in the study, I’d say yes, because you also know it’s going to help other people.”

The GI Genius AI endoscopy module is trained through reviewing more than 13 million polyp images of various shapes and sizes.

The algorithm enhances clinicians’ ability to detect polyps during a colonoscopy examination. When it detects a polyp, it alerts the physician with a visual marker on-screen acting as a ‘virtual’ second observer to the procedure.

COLO-DETECT is the first major industry study being run as part of the COLO-SPEED network which is funded by the Sir Bobby Robson Foundation, part of Newcastle Hospital’s Charity. COLO-SPEED is an innovative approach that aims to radically change how we deliver bowel cancer research – shifting the emphasis to prevention, early diagnosis and screening.

COLO-DETECT is a 2-arm, prospective, randomised controlled trial which aims to recruit over 2000 participants.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending stories